# MS DCF Valuation — Investment Banking Valuation Memo
**Date: 2026-08-20 (~10:4x ET, Thursday) — mechanical price-roll update across all five holdings, plus a NEW first-build DCF on GEHC (finally clearing the chronic 4+ week rule-6 backlog GS keeps flagging as "the cleanest name on the sheet")**

*Persona: VP-level valuation coverage for the "Claude Robinhood Trader" experiment. Coverage this run: (1) NVDA, (2) OMCL, (3) VTI, (4) VXUS, (5) XLE — all five current holdings. GS's current #1 pick (analysts/gs-stock-screener.md, 8/20 report) is again **OMCL**, already in-scope as a holding — no new name required under the strict self-feeding mandate. This cycle rotates the discretionary coverage-extension slot from FRO (built 8/19, hard pass) to **GEHC**, GS's #3 and its single most-repeated rule-6-unblock ask (4+ weeks running, escalated further this run after the CFO-succession overhang resolved — William Grogan confirmed as CFO effective 9/14). Per state.md rule 10 ("clear the oldest cross-vetting backlog when bandwidth allows"), GEHC is the right name to build now: it is a far cleaner DCF candidate than FRO (steady-state medtech FCF vs. a cyclical tanker's day-rate volatility). Prices for the five holdings are taken from state.md's freshest live Robinhood `get_portfolio` check-in (2026-08-20 ~09:36 ET, first run of the day) per rule 4. GEHC/XOM/CVX/oil inputs are WebSearch-sourced this morning (no Robinhood feed for non-holdings) and should be treated as directional, not sizing-grade, until live-verified.*

---

## Verdicts (top line)

| Ticker | Current Price | DCF Fair Value (base case) | Verdict |
|---|---|---|---|
| **NVDA** | $219.105 (8/20, ~09:36 ET, Robinhood-verified; +0.71% vs Wednesday's $217.56 close) | ~$150.6 (WACC 11%, g 3%) — unchanged model | **OVERVALUED — ~31.3% downside to DCF fair value.** Essentially flat vs. 8/19's ~31.8% (price a touch lower). No model change 6 days ahead of the 8/26 print. |
| **OMCL** | $36.235 (8/20, ~09:36 ET, Robinhood-verified; -0.54% vs Wednesday's close — seven-session green streak ends) | ~$53.89 (WACC 9%, g 3%), unchanged | **UNDERVALUED — ~48.7% upside to DCF fair value.** Widest discount on the book. External fair-value consensus nudged up to ~$57.43 this cycle (Simply Wall St) — directionally corroborates this desk's discount call. |
| **VTI** | $379.105 (-0.23%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** Unchanged. |
| **VXUS** | $87.075 (+0.12%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** Unchanged. |
| **XLE** | $64.47 (+1.40% vs Wednesday's close — day's clear leader on continued Hormuz-linked oil strength) | Composite (oil-adjusted) fair value ≈ $53.6/sh | **OVERVALUED, gap widens marginally to ≈ -16.9%** (from 8/19's -16.4%) — XLE's price outran a flat-to-lower oil-adjusted majors read. **Do not add.** |
| **GEHC** *(NEW coverage, not a holding, first build)* | $74.62 (last close, WebSearch) | **Base case ≈ $71.3/sh (WACC 8.5%, g 3%)** | **FAIRLY VALUED — ~4% mild overvaluation at base; a genuine close call (undervalued at WACC ≤8% → ~$80, overvalued at WACC ≥9% → ~$64). NOT a hard pass.** This is the first GS satellite candidate to *clear* this desk's rule-5 valuation screen — see Section 6. |

**Bottom line for the trader:** No verdict flips on any held position this cycle — all five price essentially where they did 8/19, model inputs unchanged. NVDA's 5-year CDS spread reconfirmed at 80.77bps this cycle (still below the 82bps 7/27 revisit-line; the "surpasses July peak" headline remains arithmetically wrong, as JPM has also flagged) — not a WACC trigger. **The substantive new work this cycle is GEHC.** Unlike every prior coverage-extension build this desk has run for a GS satellite ask (MU, FRO — both hard passes on valuation; XLE — overvalued, do-not-add), GEHC's DCF lands at *roughly fair value*: ~4% overvalued at the 8.5% base-WACC case, undervalued if you accept an 8% WACC (which BTIG's $79 target implicitly does), overvalued at 9%. That makes it a defensible, assumption-dependent close call — **not** a hard pass — which means for the first time a GS satellite name clears this desk's valuation gate. **The ball now moves to BW**: rule 6 requires a fresh BW risk read before GEHC is sizable, and no BW read exists yet. This desk's verdict alone does not authorize an entry, but it does — for the first time — stop being the blocker.

---

## 1. NVIDIA (NVDA) — price update, model unchanged

### What changed since 8/19
Price $219.105 (8/20, ~09:36 ET, Robinhood-verified), +0.71% vs. Wednesday's $217.56 close — a mild green open consistent with state.md's 8/20 run notes (10-year yield easing further to ~4.64-4.65%, down from Tuesday's 4.75% intraday high, on the Treasury's doubled long-dated buyback program; rule 6a buffer widening). No NVDA-specific catalyst this cycle beyond the well-worn AI-capex-financing narrative already on file. **CDS update**: fresh WebSearch reconfirms the 5-year CDS bid spread at **80.77bps** (Seeking Alpha, as of 8/18) — still arithmetically *below* the 82bps 7/27 record despite the "surpasses July peak" headline framing JPM independently flagged as internally inconsistent. Read here as confirmed-clean: no WACC action; the revisit-line requires a genuine print above 82bps, not a near-miss with a misleading headline. The August 26 print (6 days out) remains the next point at which this desk revisits the model itself, not just the price. Street consensus into the print: revenue ~$28.7B (>50% YoY), Data Center >$25B, ~94.5% implied beat odds, average PT $302.83 — none of which this desk's conservative FCF model adopts.

### Why the 5-year model still doesn't move
No new information changes any of the five build inputs (FY2027E revenue, FCF margin path, WACC, terminal growth, or the financing-guarantee treatment). The signed OpenAI/Ohio deal (8/17) remains a confirmation of an already-priced-in de-risking scenario, not a new revenue/margin data point.

### Verdict: **OVERVALUED, gap essentially unchanged**
Same 5-year build (FY2027E revenue $380B, FCF margin path 56%→48%, WACC 11% base, g 3% base):

| WACC \ Terminal g | 2.0% | 3.0% | 4.0% |
|---|---|---|---|
| **11% (base)** | $137.8 | **$150.6** | $167.1 |

Base case ($150.6) vs. today's $219.105 implies **~31.3% downside**, essentially flat vs. 8/19's ~31.8% (price ticked slightly lower). Key breakable assumptions unchanged (margin durability is the upside break; China export policy, Blackwell-Rubin execution, HBM supply bottleneck, and custom-silicon competition remain the downside breaks). **Hold, no add.** Per state.md's 8/20 ~09:36 ET run, NVDA sits ~12.16% of equity / ~10.72% of pool — comfortably below the 18-20% single-name trigger; NVDA+OMCL combined ~20.77% of equity, below the 25% combined trigger (~4.23pp buffer). Nothing here changes the 8/14 written NVDA earnings contingency plan (post-print structural-break rule, no pre-emptive trim).

---

## 2. Omnicell (OMCL) — price update, model unchanged, external fair-value corroboration

### What changed since 8/19
Price $36.235 (8/20, ~09:36 ET, Robinhood-verified) vs. $36.83 (8/19 ~15:36 read) — **the seven-session green streak ends today** (-0.54% vs. Wednesday's $36.43 close), no identifiable catalyst in either direction, consistent with GS's own read that the multi-week run was momentum/technical rather than a repricing. No fresh company news or PT actions found this cycle; the same recycled Piper Sandler ($55→$45), KeyBanc ($70→$65), and Wells Fargo ($55→$50) post-Q2 PT cuts (all 7/31-8/3) still dominate the stale WebSearch aggregators, as GS has flagged for three-plus cycles. **One genuinely useful external data point this cycle**: Simply Wall St's fair-value estimate was nudged up from $51.50 to **~$57.43**, citing the product-cycle/cabinet-refresh opportunity — directionally corroborating this desk's own undervaluation call (and the >55% consensus-PT upside on the $57.86 average target). Management's own raised FY26 adjusted-EPS guidance ($1.80-$2.00, +8.6%) further supports the base-case FCF path. Next print confirmed **11/4** (Q3), unchanged.

### Fair value and verdict (model unchanged, gap recomputed vs. today's price)
Base case fair value **$53.89** (WACC 9%, g 3% — sensitivity table unchanged since 7/30) vs. today's $36.235 implies **~48.7% upside**, marginally wider than 8/19's ~48.1% on the slightly lower price.

### Verdict: **UNDERVALUED — still the widest discount on the book**
This desk's job is valuation, not sizing. GS again has OMCL at #1 this cycle. The standing sizing gate (a fresh post-transcript BW risk sign-off) remains the only thing between this book and its widest DCF discount. This desk's fair value ($53.89) sits conservatively *below* both the Street consensus target ($57.86) and the fresh Simply Wall St estimate ($57.43) — i.e. even on this desk's more cautious model, the discount is real.

### Key assumptions that could break this model (unchanged from 8/3)
- **Upside break**: the softer Q3/bookings guide proves conservative rather than a genuine slowdown — would push fair value back toward $56-60+.
- **Downside break**: the bookings-range widening at the low end proves the first sign of a genuine demand slowdown as the platform-refresh cycle plays out — would require trimming FY27+ growth further.

---

## 3. Vanguard Total Stock Market ETF (VTI) — unchanged, brief refresh only
No change to the standing "not applicable" treatment. -0.23% on the day, a mild give-back within an otherwise constructive tape (Treasury buyback news, yields easing off the 19-year-high scare). This desk has no fair-value view on VTI and defers entirely to BR/BW on sizing and drift-band status (VTI +2.34pp of pool over target per state.md's 8/20 read, inside band).

## 4. Vanguard Total International Stock ETF (VXUS) — unchanged, brief refresh only
No change to the standing "not applicable" treatment. +0.12%, roughly flat. No DCF-based case to add or trim. Defer to BR/BW (VXUS +1.51pp of pool over target, inside band).

---

## 5. Energy Select Sector SPDR (XLE) — oil-adjusted update, gap widens marginally

### What changed since 8/19
Fresh WebSearch this morning: WTI ~$84.5 (range $84.25-84.92, modestly *lower* than 8/19's ~$85.18 input), Brent ~$93 (up ~1.5% on the day, still elevated) as the US and Iran show no sign of a Hormuz-reopening agreement — consistent with state.md's 8/20 run notes (continued Hormuz-linked strength, XLE the day's clear leader at +1.40%). XOM $164.77 (8/19 close, -0.48% — *down* from this desk's 8/19 $166.43 read) and CVX $205.76 (+0.35%, essentially flat vs. 8/19's $205.74). Data-quality note per rule 4: the initial XOM WebSearch pull again returned a stale $149-155 range, immediately discarded; the $164.77 close is consistent with the $165-166 trajectory on file.

### Oil-adjusted fair value update (mechanical)
Using 8/19's oil-adjusted fair values as the roll-forward base (XOM ~$115.86, CVX ~$214.31, built off a WTI input of ~$85.18) and applying the same ~1.2x earnings-sensitivity multiplier to today's small WTI move (~$85.18 → ~$84.5, -0.8%, i.e. a ~-1.0% fair-value adjustment):

| | XOM | CVX |
|---|---|---|
| 8/19 fair value (oil-adjusted) | $115.86 | $214.31 |
| Further oil adjustment (-~1.0%, from -0.8% WTI move × 1.2x sensitivity) | -$1.16 | -$2.14 |
| **8/20 fair value (mechanical roll)** | **~$114.70** | **~$212.17** |
| Current price (8/20, WebSearch) | $164.77 | $205.76 |
| **Implied gap** | **-30.4% (overvalued)** | **+3.1% (modestly undervalued)** |

Blended composite gap (weighted ~59.6% XOM / ~40.4% CVX): **weighted gap ≈ -16.9%**, widened marginally from 8/19's **-16.4%** — XLE's own price rose +1.40% to a fresh high while the oil-adjusted majors read ticked slightly *lower* (WTI eased, XOM's close came in below the prior read). Applied to XLE's live Robinhood-verified price ($64.47), implied fair value roughly **$53.6/sh**.

### Verdict: **OVERVALUED — gap widens marginally on price-outrunning-oil, not a fundamentals shift**
**No trim (rule 1 — no structural break, XLE is a small half-size position), no add** — this desk repeats its standing flag that the mechanical roll-forward accumulates noise over many cycles (today's price-up/oil-down divergence is itself an example), and a full ground-up composite rebuild remains overdue. The persistent ~-16 to -17% band across the last several cycles is directionally robust even through the noise: XLE is overvalued on look-through, do-not-add stands.

### Key assumptions that could break this model
- **Upside break**: an actual *signed* Hormuz reopening deal that sustainably lifts oil back toward or above GS's $80 Q4'26 house forecast would reverse the recent adjustments — though note per prior framing that a *fast* reopening more likely compresses oil (and the majors' cash flows) rather than lifting them.
- **Downside break**: continued oil/equity divergence without resolution keeps the composite gap bouncing on noise rather than settling — escalating this desk's standing rebuild flag.

---

## 6. GE HealthCare (GEHC) — NEW first-build DCF, clearing GS's chronic rule-6 backlog ask

### Why this is in scope this cycle
GS has named GEHC its top rule-6-unblock priority for 4+ consecutive weeks, calling it "the cleanest, lowest-uncertainty name on the entire sheet" (8/20 report), and this cycle flagged the one lingering overhang as resolved: **William Grogan is confirmed as CFO effective 9/14**, closing the succession question opened by Jay Saccaro's departure. BTIG reaffirmed its $79 buy target. GEHC is **not** a trader holding and **not** GS's #1 pick (OMCL holds that slot), so this sits outside the core self-feeding mandate — flagged as a discretionary coverage extension, the same slot FRO occupied 8/19, rotated now to the older, cleaner backlog item per state.md rule 10. **This build has not been requested or reviewed by BW**; per rule 6, GEHC remains fully blocked from sizing until BW's risk read is also on file, regardless of this desk's verdict.

### Business and inputs (WebSearch-sourced, flagged for data-quality)
GE HealthCare is a diversified medical-technology company (imaging, ultrasound, patient-care solutions, pharmaceutical diagnostics) spun out of GE in early 2023 — a steady-state, backlog-driven business far better suited to FCF DCF than FRO's day-rate cyclicality. Q2 2026 (reported 7/29): revenue $5.3B (+5.7% reported, +3.5% organic), adjusted EBIT margin 14.2%, adjusted EPS $1.13 (+6.6%), record backlog **$23.9B** (+$2.6B YoY). FY2026 guidance reaffirmed: **3-4% organic revenue growth, adjusted EBIT margin 15.4-15.7%, adjusted EPS $4.80-$5.00, ~$1.6B free cash flow.** Approximate scale: annual revenue ~$21B, shares outstanding ~457M (company repurchased 3.3M shares for $200M in Q2), last close $74.62 → market cap ~$34B. **Data-quality caveats, stated plainly**: (1) net debt was not precisely sourced this cycle — GEHC carries meaningful spin-related leverage; this build assumes **~$7.5B net debt** (illustrative, consistent with the post-spin balance sheet), and a materially different figure would move the per-share output; (2) share count is approximate. A full rebuild should source the actual 10-Q balance sheet. Treat the per-share figures below as directional pending live verification.

### 5-year projection (base case)
Mid-single-digit organic grower with modest margin expansion and improving FCF conversion off the FY26 $1.6B guided base:

| FY | Revenue | Growth | FCF margin | FCF |
|---|---|---|---|---|
| FY27E | $21.8B | +4% | 8.0% | $1.75B |
| FY28E | $22.7B | +4% | 8.6% | $1.95B |
| FY29E | $23.6B | +4% | 9.1% | $2.15B |
| FY30E | $24.5B | +4% | 9.6% | $2.35B |
| FY31E | $25.5B | +4% | 10.0% | $2.55B |

FCF-margin expansion (8.0%→10.0%) reflects the guided EBIT-margin ramp plus normalization of the elevated post-spin working-capital and restructuring drag; **this is the single most important — and most breakable — assumption in the build.** WACC: medtech is a defensive, stable-cash-flow sector; base **8.5%** (8% low / 9% high). Terminal g 3%.

### Sensitivity table — equity value per share (net debt ~$7.5B, ~457M shares)
| WACC \ Terminal g | 2.5% | 3.0% (base) | 3.5% |
|---|---|---|---|
| **8.0%** | $72.9 | $80.3 | $89.5 |
| **8.5% (base)** | $65.3 | **$71.3** | $78.7 |
| **9.0%** | $58.8 | $63.9 | $69.8 |

### Verdict: **FAIRLY VALUED at $74.62 — a genuine close call, NOT a hard pass**
Base case ($71.3, WACC 8.5%/g 3%) vs. $74.62 implies **~4% mild overvaluation** — but the call flips cleanly on WACC: **undervalued (~+7%) at an 8% WACC (~$80, essentially BTIG's target), overvalued (~-14%) at 9%.** This is the defining difference from every prior GS-satellite build this desk has run: MU was a hard pass, FRO a hard pass under both scenarios, XLE an overvalued do-not-add. **GEHC is the first to land inside a defensible fair-value band** — close enough that a reasonable WACC assumption tips it either way, resting on one central assumption (FCF-conversion improvement toward ~10%) rather than a heroic one. Per rule 5, a "roughly fairly valued, assumption-dependent" name is **not** a hard pass — it is a green light for the *next* gate. **This desk's verdict: GEHC clears the valuation screen; it does not by itself justify an entry, but it is no longer the blocker.** The decision now rests with BW (risk read) and BR (sizing/slot) — exactly where a clean cross-vetting candidate should sit.

### Key assumptions that could break this model
- **FCF-conversion break (primary)**: if the FY26 $1.6B FCF base does *not* expand toward ~10% margin — i.e. working-capital and restructuring drag persist — the whole build shifts down 1-2 valuation notches, tipping the base case to clearly overvalued. This is the assumption BW and a rebuild should stress first.
- **Net-debt data gap**: the ~$7.5B assumption is illustrative; the actual figure directly moves per-share fair value dollar-for-dollar on the ~457M share base.
- **Upside break**: backlog conversion accelerating (record $23.9B, +$2.6B YoY) plus faster margin expansion would support the $80+ end of the range.
- **Downside break**: tariff exposure on imported imaging components, hospital-capex softness, or a China-demand slowdown would pressure both the organic-growth and margin assumptions.

---

## Cross-check with GS screener (analysts/gs-stock-screener.md, 2026-08-20 report)
GS holds OMCL at #1 again, and this cycle supplied the sourcing explanation this desk had also inferred — the bearish "-21% past month" WebSearch framing traces to the stale 7/31-8/3 post-earnings PT cuts, not a live disagreement with the Robinhood feed; read as a lagging-data artifact, mild net positive for the thesis. GS's #3 GEHC ask is directly addressed this cycle (Section 6) — and this desk's verdict is the constructive one GS has been waiting for: GEHC clears the valuation gate. CRWD (GS #2, 6 days from its 8/26 print, ~10.5% implied move per JPM) remains rule-6 blocked with no MS DCF on file — this desk's next-most-chronic backlog item after GEHC, flagged for a future cycle (though its binary-earnings proximity argues for building it *after* the print, not into it). GS's rule-3 OXY veto stands (reinforced by continued Hormuz strength, Brent ~$93). MU, PTCT, AVGO, IONQ, FRO all remain rule-5/rule-6 blocked — FRO's 8/19 hard pass unchanged.

## Explicit read on trader's current positions (all five: NVDA, OMCL, VTI, VXUS, XLE)
**NVDA**: hold, no add — DCF does not support adding at $219.105 (~31.3% downside to base case), the widest overvaluation gap on the book. CDS spread (80.77bps) confirmed still below the 82bps revisit-line. Model unchanged pending the August 26 print, now 6 days out; the 8/14 earnings contingency plan (post-print structural-break rule, no pre-emptive trim) governs.
**OMCL**: hold, no add from this desk's chair (sizing isn't this desk's call) — DCF discount ~48.7%, still the widest gap on the book, now externally corroborated by a fresh Simply Wall St fair-value nudge to ~$57.43. The BW post-transcript sign-off remains the binding constraint.
**VTI / VXUS**: hold, no valuation view — diversified core-sleeve holdings, not DCF calls. Defer to BR/BW on drift-band status (both inside band).
**XLE**: hold, no trim, no add — do-not-add stance holds; gap widened marginally to ~-16.9% this cycle on price outrunning a flat-to-lower oil-adjusted read. Rebuild flag escalates further.
**GEHC** *(not a holding)*: this desk's DCF verdict is **fairly valued / clears the valuation gate** — the first GS satellite to do so. Not sizable until BW's risk read lands (rule 6), but this desk is no longer the blocker.

---

Sources:
- [US 10 Year Treasury Note Yield (TradingEconomics)](https://tradingeconomics.com/united-states/government-bond-yield)
- [Crude oil price today, August 20 2026 (Fortune)](https://fortune.com/article/price-of-oil-08-20-2026/)
- [Brent crude oil price (TradingEconomics)](https://tradingeconomics.com/commodity/brent-crude-oil)
- [Crude Oil WTI Aug '26 Futures (Barchart)](https://www.barchart.com/futures/quotes/CLQ26)
- [ExxonMobil (XOM) stock price history (StockAnalysis.com)](https://stockanalysis.com/stocks/xom/history/)
- [Chevron (CVX) stock price today (CNN Markets)](https://www.cnn.com/markets/stocks/CVX)
- [Nvidia's credit default swaps surpass July peak (Seeking Alpha)](https://seekingalpha.com/news/4634471-nvidias-credit-default-swaps-surpass-july-peak)
- [Nvidia Q2 FY2027 earnings preview, Aug 26 2026 (Intellectia)](https://intellectia.ai/blog/nvda-earnings-august-26-2026-preview)
- [NVDA Q2 2027 earnings report 8/26/2026 (MarketBeat)](https://www.marketbeat.com/earnings/reports/2026-8-26-nvidia-co-stock/)
- [Omnicell (OMCL) analyst consensus & 55%+ upside (DirectorsTalk)](https://www.directorstalkinterviews.com/omnicell-inc-omcl-stock-analysis-strong-analyst-consensus-with-over-55-upside-potential/4121260216)
- [Omnicell (OMCL) stock analysis, fair value ~$57.43 (Simply Wall St)](https://simplywall.st/stocks/us/healthcare/nasdaq-omcl/omnicell)
- [GE HealthCare Q2 2026 financial results (BioSpace)](https://www.biospace.com/press-releases/ge-healthcare-reports-second-quarter-2026-financial-results)
- [GE HealthCare lifts Q2 revenue 5.7%, reaffirms 2026 outlook (StockTitan)](https://www.stocktitan.net/sec-filings/GEHC/8-k-ge-health-care-technologies-inc-reports-material-event-e79d7a68ebc1.html)
- [GE HealthCare (GEHC) stock overview (StockAnalysis.com)](https://stockanalysis.com/stocks/gehc/)
- Internal: trading-experiment/state.md (8/20 ~09:36 ET live Robinhood run notes), analysts/gs-stock-screener.md (8/20 report), analysts/jpm-earnings-analyzer.md (8/20 morning report), analysts/bw-risk-assessment.md (8/19 ~14:4x ET, via git history), analysts/br-portfolio-builder.md (8/19 ~16:0x ET, via git history), analysts/ms-dcf-valuation.md (8/19 ~10:4x ET, this desk's prior report, via git history)
